<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01494285</url>
  </required_header>
  <id_info>
    <org_study_id>MA1001</org_study_id>
    <nct_id>NCT01494285</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate Tolerability and Safety of ARK-E021 Foam and to Monitor Clinical Effect in Acne Vulgaris Patients</brief_title>
  <official_title>Multicenter, Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group, Ambulatory Safety and Efficacy Study of ARK-E021 Topical Foam of 5% and 10% in Subjects With Mild to Moderate Acne Vulgaris.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M. Arkin 1999 Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vyne Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M. Arkin 1999 Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled, 3-arm, parallel-group,&#xD;
      ambulatory safety and efficacy study of ARK-E021 topical foam of 5% and 10% in subjects with&#xD;
      mild to moderate acne vulgaris.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I/II prospective, multicenter, randomized, double blind, placebo controlled,&#xD;
      parallel group, dose range finding clinical study to evaluate the safety, tolerability and&#xD;
      preliminary efficacy of ARK-E021 foam for treatment of acne vulgaris.&#xD;
&#xD;
      It is anticipated that the study will be conducted at the listed Medical Centers as well as&#xD;
      out-patient clinics at the community.&#xD;
&#xD;
      Approximately 144 male and female subjects with mild to moderate facial acne vulgaris will be&#xD;
      enrolled in this study. Following satisfaction of the entry criteria and screening&#xD;
      procedures, subjects will be randomized to either 5% or 10% topical foam (ARK-E021) or&#xD;
      placebo foam. Subjects will apply the study medication once daily on the face at bedtime for&#xD;
      12 weeks followed by a post-treatment follow up visit 4 weeks after end of treatment. The&#xD;
      first dose will be applied in the presence of the study investigator or his assignee.&#xD;
      Subsequent applications will be made by the patient.&#xD;
&#xD;
      Safety will be monitored throughout the study duration. Efficacy will be assessed by facial&#xD;
      lesion counts and by the investigator global evaluation of acne severity at baseline and at&#xD;
      weeks 3, 6, 9, 12 and 16.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of ARK-E021 topical foam in subjects with acne vulgaris.</measure>
    <time_frame>Baseline through week 16.</time_frame>
    <description>Subject safety will be assessed following treatment using measurements of the following variables:&#xD;
Physical examination.&#xD;
Vital Signs (HR, BP, Body temperature).&#xD;
Adverse events recording.&#xD;
Concomitant medications.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the efficacy of ARK-E021 topical foam in subjects with acne vulgaris.</measure>
    <time_frame>Baseline through week 16.</time_frame>
    <description>Subject efficacy will be assessed following treatment using measurements of the following variables:&#xD;
Lesion count (inflammatory/non inflammatory and total).&#xD;
Investigator global assessment (IGA; grade 0-4).&#xD;
Lesion documentation by photographs (optional).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">157</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>ARK-E021 5% foam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ARK-E021 10% foam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo foam</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARK-E021 5%</intervention_name>
    <description>Topically applied once daily at bedtime</description>
    <arm_group_label>ARK-E021 5% foam</arm_group_label>
    <other_name>Not yet marketed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARK-E021 10%</intervention_name>
    <description>Topically applied once daily at bedtime</description>
    <arm_group_label>ARK-E021 10% foam</arm_group_label>
    <other_name>Not yet marketed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Topically applied once daily at bedtime</description>
    <arm_group_label>Placebo foam</arm_group_label>
    <other_name>Not marketed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Patient is male or female between the ages of 12 to 40.&#xD;
&#xD;
          -  A clinical diagnosis of acne vulgaris with facial involvement.&#xD;
&#xD;
          -  Minimum of 15 inflammatory lesions on the face (papules and/ or pustules)but not more&#xD;
             than 40.&#xD;
&#xD;
          -  Existence of non-inflammatory lesions on the face (opened and/or closed comedones).&#xD;
&#xD;
          -  A score of â‰¥2 (moderate) on the investigator's global assessment scale.&#xD;
&#xD;
          -  Use of non oral contraceptives in female of childbearing potential during the study.&#xD;
&#xD;
          -  No known medical conditions that, in the Investigator's opinion could interfere with&#xD;
             study participation.&#xD;
&#xD;
          -  Patient is willing and able to comply with all the requirement of the study protocol.&#xD;
&#xD;
          -  Patient is willing and able to give written informed consent prior to participation in&#xD;
             the study.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Acne conglobata, acne fulminans, secondary acne (chloracne, drug induced acne), or&#xD;
             severe acne requiring systemic treatment.&#xD;
&#xD;
          -  One or more active nodule/cyst acne on the face (inactive lesions allowed).&#xD;
&#xD;
          -  Excessive facial hair (e.g. beards, sideburns, moustaches, etc.) that would interfere&#xD;
             with diagnosis or assessment of acne vulgaris.&#xD;
&#xD;
          -  Participation in another investigational drug trial within 30 days prior to study&#xD;
             entry.&#xD;
&#xD;
          -  Concomitant medication:&#xD;
&#xD;
               -  Use of systemic steroids, systemic antibiotics, systemic treatment for acne&#xD;
                  vulgaris, systemic anti-inflammatory agents within 4 weeks prior to baseline or&#xD;
                  during the study.&#xD;
&#xD;
               -  Use of topical steroids, topical antibiotics, topical treatment for acne&#xD;
                  vulgaris, topical anti-inflammatory agents within 2 weeks prior to baseline or&#xD;
                  during the study.&#xD;
&#xD;
               -  Treatment for acne with isotretinoin or isotretinoin derivatives within 12 months&#xD;
                  prior to study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>HaEmek Medical Center</name>
      <address>
        <city>Afula</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Souraski Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>December 15, 2011</study_first_submitted>
  <study_first_submitted_qc>December 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2011</study_first_posted>
  <last_update_submitted>December 1, 2013</last_update_submitted>
  <last_update_submitted_qc>December 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acne Vulgaris</keyword>
  <keyword>Topical</keyword>
  <keyword>Foam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

